CEGID
13.6.2022 16:02:10 CEST | Business Wire | Press release
Cegid, a leading provider of cloud business management solutions for finance (treasury, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors announces the acquisition of StorIQ, a London-based company with a staff of about thirty founded in 2015. The StorIQ in-store activity management platform is a valuable addition to Cegid’s retail portfolio, thereby bolstering its position as leader in retail POS solutions in France and worldwide.
StorIQ is particularly suitable for retailers with between 50 and 2,000 stores and already boasts around fifty clients including top brands such as Hugo Boss, Clarks, Douglas, Marks & Spencer International, Mountain Warehouse and Nespresso, some of which have deployed its solutions across the globe. StorIQ currently supports over 11,000 stores in more than 50 countries.
The StorIQ platform streamlines store activity planning and boosts productivity. The solution includes several modules:
- Task management and store communication: clear communication and prioritised tasks enable store managers to deliver brand standards and the expected in-store customer experience;
- Compliance: store visit reports, checklists, photo consolidation and associated reporting gives retail management teams real time visibility into store standards;
- Team Engagement: mobile learning (LMS), knowledge base and newsfeeds build employee engagement and support retention;
- Activity Planning: streamlines planning and communication for trading events and other in-store operational activity.
With 1,000 retailers running Cegid retail solutions in 75 countries, i.e. 75,000 connected stores, Cegid is helping speciality retailers and luxury brands transition to digital so as to better manage their omnichannel retail business, never miss a sale and tap into customer potential. The Cegid Retail unified commerce platform makes it possible to deliver an outstanding tailor-made shopping experience in stores worldwide. Thanks to StorIQ, the platform will now be able to cover all aspects of POS management.
StorIQ is an innovative solution built specifically for retail, and this acquisition cements Cegid’s expertise in all aspects of store operations - and further consolidates its international footprint. In addition, by improving employee experience in specialist retail, Cegid is securing its leadership in talent management.
“More than ever, the future of bricks-and-mortar stores will depend on the ability of retailers to accelerate and adapt so as to offer outstanding customer experiences as well as innovative and convenient services - while simplifying and monitoring in-store team task management. By capitalising on the current offerings of Cegid and StorIQ, brands and retailers will be able to offer an exceptional unified shopping experience across their entire store network while tapping into new sales opportunities ,” explains Cegid CEO Pascal Houillon. “Our current and future customers will be able to benefit from the optimised POS activity management offered by StorIQ paving their way to success . That’s what Retail the New Way is all about.”
StorIQ co-founder and Managing Director Amy Bastow and all the company staff will be joining the Cegid Retail Business Unit headed by Nathalie Echinard.
About StorIQ
StorIQ is a neat and intuitive retail operations app that saves time and makes life easier for store teams and retail management teams. StorIQ streamlines communications and task management, helping store teams to deliver brilliant brand standards, and retail leaders to make sure their stores get every detail right every day – maximising the value of the store estate. StorIQ is the easiest retail operations app to implement, with the most retail-specific feature set, and a world-class aftercare programme that ensures StorIQ delivers outstanding long term engagement.
StorIQ supports 11,000 stores in 55 countries, and our customers include global brands and local specialists across all sectors.
Founded in 2015, the company has around 30 employees and is based in London.
For more information: https://www.storiq.net/
About Cegid
Cegid is a leading provider of cloud business management solutions for finance (treasury, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors. With a solid full cloud business model, Cegid provides long term commitment to its customers, superior and distinctive experiences and helps companies of all sizes accelerate their digital business transformation, locally and worldwide. Cegid combines a forward looking and pragmatic approach of the business with strong capacity to innovate, an in-depth expertise in new technologies and a unique understanding of regulations and compliance. In today’s rapidly changing world, Cegid makes more possible by helping customers unleash their potential thanks to innovative and purposeful business solutions.
Bolstered by its strong international ambition and reach, Cegid has 3,600 employees and sells its solutions in 130 countries. Cegid reported annual revenues of €632 million (December 31 2021). Pascal Houillon has been the CEO since March 2017.
For more information: www.cegid.com/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005087/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
